Tolfenamic Acid Works Against Compounds That Cause Pancreatic Cancer
Main Category: Pancreatic CancerArticle Date: 23 Jun 2006 - 10:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
5 (1 votes) |
Tolfenamic acid, a non-steroidal anti-inflammatory drug (NSAID), fights pancreatic cancer by reducing the levels of some cellular proteins that contribute to tumor growth and metastasis. Stephen Safe, Ph.D., of Texas A&M University in College Station, and colleagues at the M.D. Anderson Cancer Center in Houston, Tx., used a mouse model of pancreatic cancer to investigate the anticancer activities of tolfenamic acid and related compounds.
####
Highlights in the June 21 JNCI
Contact: Stephen Safe ssafe@cvm.tamu.edu
Contact: Ariel Whitworth
Journal of the National Cancer Institute
Visit our pancreatic cancer section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/45611.php>
APA
http://www.medicalnewstoday.com/releases/45611.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




